Hepatic Steatosis and Fibrosis in Chronic Hepatitis C in Taiwan
|
|
- Lynette Armstrong
- 8 years ago
- Views:
Transcription
1 Jpn. J. Infect. Dis., 60, , 2007 Original Article Hepatic Steatosis and Fibrosis in Chronic Hepatitis C in Taiwan Meng-Hsuan Hsieh 1, Li-o Lee 2, Ming-Yen Hsieh 2, Kun-Bow Tsai 3, Jee-Fu Huang 4, Nai-Jen Hou 4, Shinn-Chern Chen 2,5, Zu-Yau Lin 2,5, Ming-Yuh Hsieh 2,5, Liang-Yen Wang 2,5, Chia-Yen Dai 1,2,5,6 *, Wan-Long Chuang 2,5 and Ming-Lung Yu 2,5 1 Department of Occupational and Environmental Medicine, 3 Department of athology, and 4 Department of Internal Medicine, Kaohsiung Municipal HsiaoKang Hospital; 2 Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital; and 5 Faculty of Internal Medicine and 6 Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan (Received May 21, Accepted September 5, 2007) SUMMARY: Hepatitis C virus (HCV) infection has been associated with hepatic steatosis. However, the role of hepatic steatosis in the pathogenesis of HCV infection remains controversial. In our study, 425 consecutive HCV-viremic patients with biopsy-proven chronic hepatitis C (male, 264; mean age, 49.0 years) were enrolled. Scoring of hepatic steatosis was based on the method described by Kleiner and on histopathology performed using the Knodell and Scheuer systems. HCV RNA level and genotypes were determined at the time of biopsy. Hepatic steatosis was observed in 30.8% of patients, including 113 mild, 16 moderate, and 3 with severe hepatic steatosis. atients with a body mass index (BMI) <23 kg/m 2 had a significantly lower rate (18.9%) of hepatic steatosis ( < 0.001). Hepatic steatosis did not correlate with the hepatic necroinflammatory activity, but was related to hepatic fibrosis ( = 0.035). Hepatic steatosis was also not associated with HCV RNA level, and the distribution was similar between patients with HCV genotype 1 and genotype 2 infection. According to multivariate analysis, BMI is the strongest risk factor associated with hepatic steatosis, followed by hepatic fibrosis and triglyceride level with odds ratios (95% confidence intervals) of 2.51 ( ), 2.06 ( ), and 1.02 ( ), respectively. Hepatic steatosis was associated with being overweight, hepatic fibrosis, and triglyceride level in chronic hepatitis C. INTRODUCTION Hepatic steatosis is a pathological phenomenon whereby fat is deposited within hepatocytes. Many factors are known to be risks for hepatic steatosis, including diabetes mellitus, hyperlipidaemia, certain drugs, and obesity (1,2). In recent years, some studies have shown that chronic hepatitis C (CHC) is also a risk factor, and indeed hepatic steatosis is associated with CHC (3,4). revious studies have shown that 30-70% of liver biopsies from patients with CHC include histological evidence of steatosis (5-7). Recent studies indicate that hepatitis C virus (HCV) core protein has a direct inhibitory effect on the function of microsomal triglyceride transfer proteins related to the secretion of very low density lipoproteins (VLDL) (8,9). Furthermore, HCV core protein is known to damage the mitochondria and therefore create oxidative stress within the hepatocytes, a process that disrupts the peroxidation of fats within hepatocytes and can lead to hepatic steatosis (5,8). In clinical observations, it remains controversial whether hepatic steatosis influences the progression of fibrosis in the liver histopathology of CHC patients. Steatosis has been reported to be independently associated with fibrosis in CHC (3,4); however, other studies have documented that steatosis is not associated with the presence of or subsequent progression to fibrosis in a cohort study group (10). Several HCV hyperendemic townships in southern Taiwan were found to have a prevalence of higher than 30% in previous studies *Corresponding author: Mailing address: Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, 100 Tzyou 1st Rd, Kaohsiung City 807, Taiwan. Tel: ext. 7475, Fax: , d820195@yahoo.com.tw (11,12). Given that hepatic steatosis may therefore be an important histopathological factor in CHC, the aim of this study was to establish the prevalence of hepatic steatosis in Taiwanese CHC patients and to evaluate whether hepatic steatosis was related to the virological characteristics of HCV and the histopathological features of liver biopsy. In addition, the association between hepatic steatosis and anthropometric and biometabolic markers in CHC patients was also explored. MATERIALS AND METHODS atients: A total of 425 consecutive CHC patients were enrolled at the Kaohsiung Municipal Hsiao-Kang Hospital (a regional core hospital) and Kaohsiung Medicine University Hospital (a medical center) from August 1998 to March They were all seropositive for antibody to HCV (anti- HCV) for more than 6 months, and positive for HCV RNA. All patients underwent liver biopsies and were proven to have CHC. The patients medical histories were taken and their body mass index (BMI) was measured on the date of their liver biopsy. Hypertension was determined according to the criteria defined by the National Committee on revention, Detection, Evaluation, and Treatment of High Blood ressure (13). atients with diabetes mellitus were classified according to the diagnostic criteria of the National Diabetes Data Group (14), or if the patient s past history mentioned taking oral hypoglycemic agents (OHA) or injecting insulin to control blood sugar. Hyperlipidaemia was defined as the fasting lipid criterion according to the third report of the National Cholesterol Education rogram (NCE) Expert anel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment anel III) final report (15). atients were classified as overweight if their BMI was greater 377
2 than or equal to 23 kg/m 2, according to the Asia-acific BMI criteria (16). atients were excluded if they were diagnosed with coexisting hepatocellular carcinoma, decompensated cirrhosis or hepatic failure, other hepatic diseases (such as Wilson s disease or 1-antitrypsin deficiency), biliary system disease, pancreatic disease or other severe systemic diseases (such as renal failure), or if concurrent hepatitis B or human immunodeficiency virus infection was present. atients with a history of alcohol consumption exceeding 40 g/day or those diagnosed with alcoholism, intravenous drug abuse, or exposure to hepatotoxic drugs were also excluded. Liver histopathology: Liver biopsy samples of at least 2 cm in length were taken and stored 4 C in a refrigerator for 8 h, before being reversed in a freezer under 70 C. Biopsy samples were stained with hematoxylin and eosin, and the results were then reported by one pathologist. The degree of hepatic necroinflammatory change was classified according to the histological activity index (HAI) score system (17), and the fibrosis stage was set according to the Scheuer scale (18). The extent of hepatic steatosis was assessed by light microscopy and graded as none (0-5%), mild (5-33%), moderate (33-66%), and severe (>66%), according to the area occupied by fatty hepatocytes (19). Laboratory tests: The presence of anti-hcv was tested by using third generation enzyme-linked immunosorbent assay kits (Abbott, North Chicago, Ill., USA). HCV RNA was detected using a standardized automated qualitative reverse transcription-polymerase chain reaction (CR) assay (COBAS AMLICOR Hepatitis C Virus Test, version 2.0; Roche, Branchburg, N.J., USA), with a detection limit of 50 IU/mL. HCV RNA levels were detected with a branched DNA assay (Versant HCV RNA 3.0; Bayer, Emeryville, Calif., USA), performed strictly in accordance with the manufacturer s instructions. Quantification was limited to 615 IU of HCV RNA per ml. HCV genotypes (1a, 1b, 2a, 2b, and 3a) were determined through amplification of the core region using genotype-specific primers (20). All data were collected at the time of the liver biopsies. Statistical analysis: The statistical tests used were Student s t test, the Mann-Whitney test, 2 square test, and Fisher exact test. All of these tests are two-sided, and the significance levels were set at = Logistic regression analysis was performed to determine the factors associated with hepatic fibrosis based on the odds ratio and 95% confident intervals for these covariates. The covariates analyzed were age, sex, hypertension, diabetes mellitus, hyperlipidaemia, HCV genotype, HCV viral load, BMI, and hepatic necroinflammatory activity and fibrosis. The procedures were performed using the SSS 12.0 statistical package (SSS, Inc., Chicago, Ill., USA). Table 1. Basic demographics and factors associated with steatosis and non-steatosis patients in chronic hepatitis C patients atient Steatosis 1) ( ) Steatosis 1) (+) Fibrosis ( ) Fibrosis 2) (+) No. (%) No. (%) No. (%) No. (%) No. (%) No. of case 425 (100) 293 (68.2) 132 (30.8) 91 (21.4) 334 (78.6) Age (y) (mean ± SD) 49.0 ± ± ± ± ± ) Sex Male 264 (62.1) 177 (60.4) 87 (65.9) (70.3) 200 (59.9) 0.07 Female 161 (37.9) 116 (39.6) 45 (34.1) 27 (29.7) 134 (40.1) Hypertension 3) Without 357 (84.0) 250 (85.3) 107 (81.1) (91.2) 274 (82.0) ) With 68 (16.0) 43 (14.7) 25 (18.9) 8 (8.8) 60 (18.0) Diabetes mellitus 4) Without 384 (90.4) 267 (91.1) 117 (88.6) (93.4) 299 (89.5) 0.27 With 41 (9.6) 26 (8.9) 15 (11.4) 6 (6.6) 35 (10.5) Hyperlipidemia 5) Without 407 (95.8) 282 (96.2) 125 (94.7) (93.4) 322 (96.4) 0.21 With 18 (4.2) 11 (3.8) 7 (5.3) 6 (6.6) 12 (3.6) Triglyceride ± ± ± 36.6 < ) ± ± Cholesterol ± ± ± ± ± BMI (kg/m 2 ) (mean ± SD) 24.8 ± ± ± 3.20 < ) 24.0 ± ± < 23 kg/m (32.0) 111 (37.9) 25 (18.9) < ) 33 (36.3) 103 (30.8) kg/m (68.0) 182 (62.1) 107 (81.1) 58 (63.7) 231 (69.2) HCV genotype Type 1b 246 (57.9) 174 (59.4) 72 (54.5) (53.8) 197 (59.0) 0.74 Type 2a 140 (32.9) 96 (32.8) 44 (33.3) 32 (35.2) 108 (32.3) Type 2b 33 (7.8) 19 (6.5) 14 (10.6) 9 (9.9) 24 (7.2) Type unclassified 6 (1.4) 4 (1.4) 2 (1.5) 1 (1.1) 5 (1.5) Viral load log IU/ml (mean ± SD) 5.20 ± ± ± ± ± < IU/ml 233 (54.8) 155 (52.9) 78 (59.1) (52.7) 185 (55.4) IU/ml 192 (45.2) 138 (47.1) 54 (40.9) 43 (47.3) 149 (44.6) AST, IU/L (mean ± SD) 99.9 ± ± ± ± ± ) ALT, IU/L (mean ± SD) ± ± ± ± ± ) :Steatosis grade was according to criteria of Kleiner et al. (19). 2) :Fibrosis stage was according to criteria of Scheuer,.J. (18). 3) :Hypertension was determined according to the criteria defined by the National Committee on revention, Detection, Evaluation, and Treatment of High Blood ressure (13). 4) :atients with diabetes mellitus were classified if they met diagnostic criteria of the National Diabetes Data Group (14), or if patient past history mentioned taking oral hypoglycemic agents (OHA) or injecting insulin for controlling blood sugar. 5) : Hyperlipidemia was defined as the fasting lipid criteria according to the third report of the National Cholesterol Education rogram (NCE) Expert anel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment anel III) final report (15). 6) :In univariate analysis, triglyceride level and BMI were related to hepatic steatosis. 7) : In univariate analysis, age, hypertension history, and AST level were related to hepatic fibrosis. BMI, body mass index; AST, aspartate aminotransferase; ALT, alanine aminotransferase. 378
3 RESULTS Table 1 shows the basic demographics of 425 CHC patients, of whom 264 (62.1%) were male. The average age was 49.0 ± 12.2 years and the mean BMI was 24.8 ± 3.60 kg/ m 2. The prevalence of hypertension, diabetes mellitus, and hyperlipidaemia were 16.0, 9.6, and 4.2%, respectively. The HCV genotype distribution was as follows: 1b in 246 (57.9%) patients, 2a in 140 (32.9%) patients, 2b in 33 (7.8%) patients, and unclassified in 6 (1.4%) patients. The mean levels of HCV viral load, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) were 5.20 ± 1.23 logs IU/ml, 99.9 ± 77.8 IU/L, and ± IU/L, respectively. One hundred and thirty-two (30.8%) patients had hepatic steatosis, of which 113 (85.7%), 16 (12.1%), and 3 (2.3%) were graded as mild, moderate, and severe steatosis, respectively. Factors associated with hepatic steatosis and fibrosis: A comparison of the results of covariates between patients with and without steatosis is shown in Table 1. The mean BMI and triglyceride level of the steatosis group were significantly higher than those of the non-steatosis group (26.0 ± 3.20 versus 24.3 ± 3.66, < 0.001; and ± 36.6 versus 96.2 ± 29.9, < 0.001). The prevalence of obesity (BMI > 23 kg/m 2 ) was significantly higher in the steatosis group than the non-steatosis group (81.1 versus 62.1%, < 0.001). The presence of hepatic steatosis was not related to sex, age, cholesterol level, HCV viral load and genotype, hepatic enzymes or a history of hypertension, diabetes, or hyperlipidemia. In univariate analysis, hepatic fibrosis was found to be associated with age, the presence of hypertension, and serum AST levels (Table 1). The relationship between hepatic histopathology and steatosis is shown in Table 2. There was no difference in hepatic necroinflammatory activity between patients with and without steatosis. atients with hepatic steatosis had significantly higher rates of hepatic fibrosis than those without hepatic steatosis (84.8 versus 75.8%, = 0.035). The independent predictive values of age, sex, HCV genotype and viral load, hepatic necroinflammatory activity and fibrosis, hypertension, diabetes, triglyceride and cholesterol levels, BMI, and liver enzymes were determined by using multivariate logistic regression analysis. BMI, fibrosis, and triglyceride levels were significant factors correlating with hepatic steatosis in CHC patients (Table 3). Hepatic steatosis, age, and periportal bridging necrosis were significant factors related to hepatic fibrosis in CHC patients (Table 4). Table 2. Histopathologic presence in chronic hepatitis C patients Steatosis Steatosis 1) ( ) Steatosis 1) (+) No. (%) No. (%) Intralobular degeneration and focal necrosis 3) Score (91.1) 119 (90.2) 0.75 Score (8.9) 13 (9.8) ortal inflammation 3) Score (35.8) 51 (36.8) 0.58 Score (64.2) 81 (61.4) eriportal ± bridging necrosis 3) Score (71.7) 90 (68.2) 0.47 Score (28.3) 42 (31.8) Total necroinflammatory score 3) Score (90.8) 117 (88.6) 0.49 Score > 8 27 (9.2) 15 (11.4) Fibrosis stage 2) Stage 0 71 (24.2) 20 (15.2) ) Stage (75.8) 112 (84.8) 1) : See Table 1, footnote 1). 2) : See Table 1, footnote 2). 3) :Hepatic necroinflammatory grade was according to the histological activity index (HAI) score system. 4) : In univariate analysis, fibrosis stage was related to hepatic steatosis. Table 3. Multivariates logistic regression analysis for factors associated with hepatic steatosis in chronic hepatitis C patients Factor Comparison Odds ratio 95% confidence interval BMI <23 kg/m 2 = 0, 23 kg/m 2 = Hepatic fibrosis F0 = 0, F1-4 = Triglyceride per 1 mg/dl increase <0.001 BMI, body mass index. Table 4. Multivariates logistic regression analysis for factors associated with hepatic fibrosis in chronic hepatitis C patients Factor Comparison Odds ratio 95% confidence interval eriportal ± bridging necrosis score 0-1 = 0, score 3-10 = <0.001 Hepatic steatosis absence = 0, presence = Age per 1 year increase
4 DISCUSSION In our study, 30.8% of Taiwanese CHC patients had hepatic steatosis. This figure is similar to that previously reported in western countries (5,6). BMI is the strongest risk factor associated with hepatic steatosis, followed by hepatic fibrosis and age. Hwang et al. (7) have reported that 52% of patients with CHC had hepatic steatosis in northern Taiwan, and that average BMI values (24.5 ± 3.9) were higher in patients with hepatic steatosis. Leandro et al. (21) have reported a metaanalysis involving 10 centers in Italy, Switzerland, France, Australia, and United States in which 93% of the subjects were Caucasian. Their results also showed a higher prevalence of steatosis (50.9%) than that found in our study. BMI value and age were related to hepatic steatosis, and hepatic steatosis and age were correlated with hepatic fibrosis in CHC patients. The inconsistency in the prevalence rate of hepatic steatosis in CHC may be due to the fact that factors such as case number, residual area, obesity definition, clinical features, patients recruitment biases, and varying the inclusion/ exclusion criteria were different between our study and the other two studies. revious anthropometric data showed that for a given BMI, Asians (mostly Chinese) have more body fat in a more prominent central distribution than Caucasians (22-24). No similar data were studied in CHC patients, and it remains unclear whether ethnicity is associated with a different prevalence rate of hepatic steatosis in CHC. This topic requires further study. Day and James (25) proposed the two hits theory. The first hit is peripheral insulin resistance, which leads to increased lipolysis and delivery of free fatty acids (FFA) to the liver. These events may in turn result in triglyceride accumulation (26) and may lead to hepatic steatosis. The second hit is the accumulation of triglycerides in hepatocytes, which will increase fatty acid -oxidation which, in the presence of mitochondrial abnormalities, would result in free radical formation, consequent cell injury, inflammation, and fibrosis (27). The results of previous studies (7,10) and of ours indicate that triglyceride levels were correlated with hepatic steatosis, a finding that is consistent with Day and James theory (25). Furthermore, the increased risk of hepatic steatosis with increasing BMI may reflect increasing insulin resistance, which also causes intracellular -oxidation, mitochondria damage, and fat deposition within the hepatocyte (28). Our study and previous studies (7,21,29) showed that raised BMI in patients with CHC could be used as an indicator of risk for concurrent hepatic steatosis, even though the threshold of BMI values differed in different studies. It therefore appears that metabolic factors, especially higher BMI values, really do reflect an increased risk for hepatic steatosis in CHC patients, irrespective of whether or not they are Taiwanese or Caucasians. The presence of a history of diabetes mellitus, hypertension or hyperlipidemia was not associated with hepatic steatosis. A possible explanation for this is that these patients are on medication for these conditions, which alters their blood pressure, blood sugar, and lipid profile. In addition, the only a small number of such patients have been studied, especially patients with hyperlipidemia history. Our results showed that there was a relationship between age and hepatic steatosis. revious research has suggested that patients with both CHC and hepatic steatosis are more likely to have had CHC for a longer period than patients without hepatic steatosis. It therefore follows that the length of time of exposure to HCV can affect the incidence of hepatic steatosis (30,31). However, our results showed that patients with hepatic steatosis were younger than those without steatosis, and that age was not related to hepatic steatosis. These results differ from the report of Leandro et al. (21), which indicated that older age was associated with a higher risk of steatosis. We did not find evidence for possible causes that correlated with steatosis incidence, and further investigation is required to address this issue. In contrast, the mean age of patients with fibrosis was higher in our study. This result is similar to that found by Leandro et al. (21). We suggest that patients with longer periods of HCV infection have a higher rate of developing hepatic fibrosis, because slow and steady histopathologic progression (such as necroinflammation or fibrosis) is found in most untreated patients with chronic HCV infection. CHC may cause virus-induced inflammatory changes that lead to increased oxidative stress, increased peroxidation, increased production of cytokines, and ultimately, cell death (28,32). It has been noted that HCV genotype type 3 creates greater DNA oxidative damage, and therefore we thought that the genotype of hepatitis C might also be a possible factor influencing the progression to hepatic steatosis (6). Oxidative stress can induce the peroxidation of fat, which can lead to hepatic steatosis (5,8). HCV core protein can directly inhibit the function of microsomal triglyceride transfer proteins and the secretion of VLDL from hepatocytes (8,9). In this way, HCV core protein itself can induce oxidative stress and mitochondrial damage. Hepatic steatosis is thought to precede hepatic fibrosis irrespective of the HCV genotype causing hepatitis, but it is particularly common following genotype 3 CHC (21,33). Leandro et al. (21) showed that genotype 3 CHC was related to hepatic steatosis; however, HCV genotype 3 is very rare in Taiwan (12), and our results showed that the rate at which hepatic steatosis is present is similar between patients with genotype 1 and genotype 2. In addition, our study and Hwang et al. s study (7) pointed out that HCV viral load was not related to hepatic steatosis. Our study documents that virological factors play little role in hepatic steatosis in Taiwanese CHC patients, and that metabolic factors are important for this condition. revious studies have also indicated that patients with HCV infection and histological evidence of steatosis are at greater risk of progressing to hepatic fibrosis (34). Hwang et al. (7) have pointed out that necroinflammation is not specifically related to hepatic steatosis, but that the stage of hepatic fibrosis is generally more advanced in patients with hepatic steatosis compared to those without steatosis. Leandro et al. (21) and Yoon and Hu (33) believed that hepatic steatosis is an important and independent risk factor for developing hepatic fibrosis in CHC infection. However, one study performed by erumalswami et al. (10) suggested that hepatic steatosis was not related to hepatic fibrosis in CHC infection. In our study, hepatic steatosis was found to be related to fibrosis, and vice versa. Necroinflammatory conditions, such as intralobular degeneration and focal necrosis, portal inflammation, and periportal and/or bridging necrosis, were not significantly related to hepatic steatosis. However, we did not observe a positive correlation between the grade of hepatic steatosis and the severity of hepatic fibrosis in our CHC patients. This might be due to the fact that the number of cases of moderate and severe hepatic steatosis was too limited in our series for us to make a meaningful comparison between the severity of hepatic fibrosis and steatosis. The possible causes for patients with hepatic fibrosis having a 380
5 higher risk for steatosis are still unclear. We propose that hepatic fibrosis is multifactorial and is associated with older age, possibly due to the likelihood of a longer period of CHC infection and higher probable contact with factors that cause hepatic steatosis. The reasons for the different results concerning hepatic steatosis and fibrosis among many studies are not well understood. Further studies are needed to clarify the controversy. Furthermore, in our study, hypertension was found to correlate with hepatic fibrosis in univariate analysis, but not in multivariate analysis. We hypothesized that this may be due to an increased average age in the hepatic fibrotic group and a greater prevalence of hypertension in this group. In addition, hypertension was also not related to hepatic steatosis, which was related to hepatic fibrosis in our study. However, the fact that no association was found using multivariate analysis suggests that hypertension is not a risk factor for hepatic fibrosis in CHC patients. This issue should be studied further in the future. In conclusion, we demonstrated that 30.8% of Taiwanese patients with CHC had hepatic steatosis, with most of these cases graded as mild. BMI was the strongest risk factor associated with hepatic steatosis, followed by hepatic fibrosis and triglyceride level for CHC patients in Taiwan. ACKNOWLEDGMENTS This study was supported by grants from Taiwan Liver Research Foundation, Taiwan. REFERENCES 1. Angulo,. and Lindor, K.D. (2002): Non-alcoholic fatty liver disease. J. Gastroenterol. Hepatol., 17, Suppl., S Angulo,. (2002): Nonalcoholic fatty liver disease. N. Engl. J. Med., 346, Hourigan, L.F., Macdonald, G.A., urdie, D., et al. (1999): Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology, 29, Castera, L., Hezode, C., Roudot-Thoraval, F., et al. (2003): Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies. Gut, 52, Bondini, S. and Younossi, Z.M. (2006): Non-alcoholic fatty liver disease and hepatitis C infection. Minerva Gastroenterol. Dietol, 52, owell, E.E., Jonsson, J.R. and Clouston, A.D. (2005): Steatosis: cofactor in other liver diseases. Hepatology, 42, Hwang, S.J., Luo, J.C., Chu, C.W., et al. (2001): Hepatic steatosis in chronic hepatitis C virus infection: prevalence and clinical correlation. J. Gastroenterol. Hepatol., 16, Zekry, A., McHutchison, J.G. and Diehl, A.M. (2005): Insulin resistance and steatosis in hepatitis C virus infection. Gut, 54, Mirandola, S., Realdon, S., Iqbal, J., et al. (2006): Liver microsomal triglyceride transfer protein is involved in hepatitis C liver steatosis. Gastroenterology, 130, erumalswami,., Kleiner, D.E., Lutchman, G., et al. (2006): Steatosis and progression of fibrosis in untreated patients with chronic hepatitis C infection. Hepatology, 43, Chuang, W.L., Yu, M.L., Dai, C.Y., et al. (2006): Treatment of chronic hepatitis C in southern Taiwan. Intervirology, 49, Yu, M.L., Chuang, W.L., Chen, S.C., et al. (2001): Changing prevalence of hepatitis C virus genotypes: molecular epidemiology and clinical implications in the hepatitis C virus hyperendemic areas and a tertiary referral center in Taiwan. J. Med. Virol., 65, Sixth Report of the Joint National Committee on revention, Detection, Evaluation, and Treatment of High Blood ressure (1997): Arch. Intern. Med., 157, American Diabetes Association (1997): Clinical practice recommendations Diabetes Care, 20, Suppl. 1, S Third Report of the National Cholesterol Education rogram (NCE) Expert anel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment anel III) final report (2002): Circulation, 106, Chang, C.J., Wu, C.H., Chang, C.S., et al. (2003): Low body mass index but high percent body fat in Taiwanese subjects: implications of obesity cutoffs. Int. J. Obes. Relat. Metab. Disord., 27, Knodell, R.G., Ishak, K.G., Black, W.C., et al. (1981): Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology, 1, Scheuer,.J. (1991): Classification of chronic viral hepatitis: a need for reassessment. J. Hepatol., 13, Kleiner, D.E., Brunt, E.M., Van Natta, M., et al. (2005): Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology, 41, Okamoto, H., Tokita, H., Sakamoto, M., et al. (1993): Characterization of the genomic sequence of type V (or 3a) hepatitis C virus isolates and CR primers for specific detection. J. Gen. Virol., 74 ( t 11), Leandro, G., Mangia, A., Hui, J., et al. (2006): Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a metaanalysis of individual patient data. Gastroenterology, 130, Zafrani, E.S. (2004): Non-alcoholic fatty liver disease: an emerging pathological spectrum. Virchows Arch., 444, Rattarasarn, C., Leelawattana, R., Soonthornpun, S., et al. (2004): A. Gender differences of regional abdominal fat distribution and their relationships with insulin sensitivity in healthy and glucose-intolerant Thais. J. Clin. Endocrinol. Metab., 89, i-sunyer, F.X. (2004): The epidemiology of central fat distribution in relation to disease. Nutr. Rev., 62, S Day, C.. and James, O.F. (1998): Steatohepatitis: a tale of two hits? Gastroenterology, 114, Nammi, S., Koka, S., Chinnala, K.M., et al. (2004): Obesity: an overview on its current perspectives and treatment options. Nutr. J., 3, Dixon, J.B., Bhathal,.S. and O Brien,.E. (2001): Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology, 121, Farrell, G.C. and Larter, C.Z. (2006): Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology, 43, S99-S Younossi, Z.M., McCullough, A.J., Ong, J.., et al. (2004): Obesity and non-alcoholic fatty liver disease in chronic hepatitis C. J. Clin. Gastroenterol., 38, Cornianu, M., Dema, A. and Taban, S., et al. (2005): Hepatic steatosis associated with hepatitis C virus infection. Rom. J. Morphol. Embryol., 46, Stransky, J., Ryzlova, M., Stritesky, J., et al. (2002): [Aspartate aminotransferase (AST) more than alanine aminotransferase (ALT) levels predict the progression of liver fibrosis in chronic HCV infection]. Vnitr. Lek., 48, (in Czech). 32. Robertson, G., Leclercq, I. and Farrell, G.C. (2001): Nonalcoholic steatosis and steatohepatitis. II. Cytochrome -450 enzymes and oxidative stress. Am. J. hysiol. Gastrointest. Liver hysiol., 281, G Yoon, E.J. and Hu, K.Q. (2006): Hepatitis C virus (HCV) infection and hepatic steatosis. Int. J. Med. Sci., 3, Westin, J., Nordlinder, H., Lagging, M., et al. (2002): Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. J. Hepatol., 37,
Boehringer Ingelheim- sponsored Satellite Symposium. HCV Beyond the Liver
Boehringer Ingelheim- sponsored Satellite Symposium HCV Beyond the Liver HCV AS A METABOLIC MODIFIER: STEATOSIS AND INSULIN RESISTANCE Francesco Negro University Hospital of Geneva Switzerland Clinical
More informationConveners: S. Bruno, C.M. Mastroianni
SESSIONE 2 Oral communications based on selected abstracts Conveners: S. Bruno, C.M. Mastroianni PNPLA3 variant is an independent predictor of severe steatosis in patients with chronic hepatitis C and
More informationNASH: It is not JUST a Fatty Liver. Karen F. Murray, M.D. Director of Hepatobiliary Program Children s Hospital and Regional Medical Center
NASH: It is not JUST a Fatty Liver Karen F. Murray, M.D. Director of Hepatobiliary Program Children s Hospital and Regional Medical Center Stages of Fatty Liver Disorders Fatty Liver 16-35% of Western
More informationMolecular Diagnosis of Hepatitis B and Hepatitis D infections
Molecular Diagnosis of Hepatitis B and Hepatitis D infections Acute infection Detection of HBsAg in serum is a fundamental diagnostic marker of HBV infection HBsAg shows a strong correlation with HBV replication
More informationFat and Viral Liver Disease
Fat and Viral Liver Disease Francesco Negro Viropathology Unit University of Geneva Medical Center Geneva, Switzerland Mainz, September 20, 2008 Steatosis and HBV Steatosis in HBV infection: prevalence
More informationTwo Cases of Non-Alcoholic Steato-Hepatitis Developing from Simple Fatty Liver
case series Two Cases of Non-Alcoholic Steato-Hepatitis Developing from Simple Fatty Liver Soo Ryang Kim, Taisuke Nakajima, Kenji Ando, Keiji Mita, Katsumi Fukuda Department of Gastroenterology, Kobe Asahi
More informationWorsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies
288 LIVER DISEASE Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies L Castéra, C Hézode, F Roudot-Thoraval,
More informationTHE ENDOCANNABINOID SYSTEM AS A THERAPEUTIC TARGET FOR LIVER DISEASES. Key Points
December 2008 (Vol. 1, Issue 3, pages 36-40) THE ENDOCANNABINOID SYSTEM AS A THERAPEUTIC TARGET FOR LIVER DISEASES By Sophie Lotersztajn, PhD, Ariane Mallat, MD, PhD Inserm U841, Hôpital Henri Mondor,
More informationRisk Factors for Alcoholism among Taiwanese Aborigines
Risk Factors for Alcoholism among Taiwanese Aborigines Introduction Like most mental disorders, Alcoholism is a complex disease involving naturenurture interplay (1). The influence from the bio-psycho-social
More information2.1 AST can be measured in heparin plasma or serum. 3 Summary of clinical applications and limitations of measurements
Aspartate aminotransferase (serum, plasma) 1 Name and description of analyte 1.1 Name of analyte Aspartate aminotransferase (AST) 1.2 Alternative names Systematic name L aspartate:2 oxoglutarate aminotransferase
More informationAlanine aminotransferase (serum, plasma)
Alanine aminotransferase (serum, plasma) 1 Name and description of analyte 1.1 Name of analyte Alanine aminotransferase (ALT) 1.2 Alternative names Systematic name L alanine:2 oxoglutarate aminotransferase
More informationHepatitis C Monitoring and Complications (and Treatment!) Dr Mark Douglas
Hepatitis C Monitoring and Complications (and Treatment!) Dr Mark Douglas Hepatitis C Virus Shimizu et al., 1996 Positive single strand RNA virus Flaviviridae family, Hepacivirus genus 9.6 kbp genome ~3000
More informationBACKGROUND MEDIA INFORMATION Fast facts about liver disease
BACKGROUND MEDIA INFORMATION Fast facts about liver disease Liver, or hepatic, disease comprises a wide range of complex conditions that affect the liver. Liver diseases are extremely costly in terms of
More informationPeg-IFN and ribavirin: what sustained virologic response can be achieved by using HCV genotyping and viral kinetics?
Peg-IFN and ribavirin: what sustained virologic response can be achieved by using HCV genotyping and viral kinetics? Prof. I. Bakulin Gastroenterology Department Key Questions Background Worldwide prevalence
More informationBURDEN OF LIVER DISEASE IN BRAZIL
BURDEN OF LIVER DISEASE IN BRAZIL Burden of Liver Disease in Europe Blachier et al. J Hepatol 58:593, 2013 Review of 260 epidemiologic studies of the 5 previous years Cirrhosis is responsible for 170.000
More informationNon-alcoholic fatty liver disease: Prognosis and Treatment
Non-alcoholic fatty liver disease: Prognosis and Treatment Zachary Henry, M.D. Assistant Professor UVA Gastroenterology & Hepatology October 28, 2015 Overview Case Presentation Prognosis Effects of fibrosis
More informationNP/PA Clinical Hepatology Fellowship Summary of Year-Long Curriculum
OVERVIEW OF THE FELLOWSHIP The goal of the AASLD NP/PA Fellowship is to provide a 1-year postgraduate hepatology training program for nurse practitioners and physician assistants in a clinical outpatient
More informationHEPATITIS WEB STUDY Acute Hepatitis C Virus Infection: Epidemiology, Clinical Features, and Diagnosis
HEPATITIS WEB STUDY Acute C Virus Infection: Epidemiology, Clinical Features, and Diagnosis H. Nina Kim, MD Assistant Professor of Medicine Division of Infectious Diseases University of Washington School
More informationHepatitis C Glossary of Terms
Acute Hepatitis C A short-term illness that usually occurs within the first six months after someone is exposed to the hepatitis C virus (HCV). 1 Antibodies Proteins produced as part of the body s immune
More informationCirrhosis and HCV. Jonathan Israel M.D.
Cirrhosis and HCV Jonathan Israel M.D. Outline Relationship of fibrosis and cirrhosisprevalence and epidemiology. Sequelae of cirrhosis Diagnosis of cirrhosis Effect of cirrhosis on efficacy of treatment
More information"Lucian Blaga"University Sibiu Faculty of Medicine Victor Papilian. EVALUATION OF LIVER FIBROSIS IN CHRONIC VIRAL HEPATITIS C. PhD thesis abstract
"Lucian Blaga"University Sibiu Faculty of Medicine Victor Papilian EVALUATION OF LIVER FIBROSIS IN CHRONIC VIRAL HEPATITIS C. PhD thesis abstract Scientific coordinator Prof. Dr. Mircea DEAC PhD student
More informationPrimary Care Guidance Program: Non-Alcohol related Fatty Liver Disease (NAFLD) Guidance on Management in Primary Care
Primary Care Guidance Program: Non-Alcohol related Fatty Liver Disease (NAFLD) Guidance on Management in Primary Care This advice has been developed to help GPs with shared care of patients with Non- Alcohol
More informationCo-infected health-care workers
Co-infected health-care workers Y.Yazdanpanah Service Universitaire des Maladies Infectieuses et du Voyageur C.H. Tourcoing, Faculté de Médecine de Lille CNRS U362, Lille, France Co-infected health-care
More informationAlcoholic Liver Disease and Its Relationship with Metabolic Syndrome
Research and Reviews Alcoholic Liver Disease and Its Relationship with Metabolic Syndrome JMAJ 53(4): 236 242, 2010 Hiromasa ISHII,* 1 Yoshinori HORIE,* 2 Yoshiyuki YAMAGISHI,* 3 Hirotoshi EBINUMA* 3 Abstract
More informationManagement of hepatitis C: pre- and post-liver transplantation. Piyawat Komolmit Bangkok
Management of hepatitis C: pre- and post-liver transplantation Piyawat Komolmit Bangkok Liver transplantation and CHC Cirrhosis secondary to HCV is the leading cause of liver transplantation in the US
More informationHCV Treatment Failure
بسم االله الرحمن الرحيم HCV Treatment Failure Gamal Esmat PROF.OF HEPATOLOGY&TROPICAL MEDICINE CAIRO UNIVERSITY Director of Viral Hepatitis Treatment Centers (VHTCs( VHTCs) MOH-EGYPT www.gamalesmat.com
More informationRole of Body Weight Reduction in Obesity-Associated Co-Morbidities
Obesity Role of Body Weight Reduction in JMAJ 48(1): 47 1, 2 Hideaki BUJO Professor, Department of Genome Research and Clinical Application (M6) Graduate School of Medicine, Chiba University Abstract:
More informationThe Natural History of Chronic Hepatitis B Virus Infection
The Natural History of Chronic Hepatitis B Virus Infection Brian J. McMahon, M.D. 1 ABSTRACT Three stages of chronic hepatitis B virus (HBV) infection are recognized: the immune tolerant phase, the chronic
More informationViral Hepatitis Case Report
Page 1 of 9 Viral Hepatitis Case Report Perinatal Hepatitis B Virus Infection Michigan Department of Community Health Communicable Disease Division Investigation Information Investigation ID Onset Date
More informationMedical publications on HBV and HCV Coinfection
Recent advances of HBV and HCV co-infection 台 中 榮 總 內 科 部 胃 腸 肝 膽 科 呂 宜 達 醫 師 2013.03.28 Outline Epidemiology of HBV and HCV coinfection Clinical significance of HBV and HCV coinfection Interplay between
More informationIS VITAMIN E SAFE TO USE?
Vitamin E & Fatty Liver IS VITAMIN E SAFE TO USE? Nonalcoholic Fatty Liver Disease (NAFLD) & Nonalcoholic Steatohepatitis (NASH) Prevalence: 5.7-16.5% 57 5 in US Usually diagnosed in 40-60 y/o s Non-significant
More informationNon Alcoholic Steato-Hepatitis (NASH)
Non Alcoholic Steato-Hepatitis (NASH) DISCLAIMER NEITHER THE PUBLISHER NOR THE AUTHORS ASSUME ANY LIABILITY FOR ANY INJURY AND OR DAMAGE TO PERSONS OR PROPERTY ARISING FROM THIS WEBSITE AND ITS CONTENT.
More informationAbnormal Liver Function. Dr William Alazawi MA(Cantab) PhD MRCP Senior Lecturer and Consultant in Hepatology Queen Mary, University of London
Abnormal Liver Function Dr William Alazawi MA(Cantab) PhD MRCP Senior Lecturer and Consultant in Hepatology Queen Mary, University of London Does Liver Disease Matter? Mortality in England & Wales Liver-related
More informationHepatitis C virus (HCV) genotype plays an important
Rapid Virological Response and Treatment Duration for Chronic Hepatitis C Genotype 1 Patients: A Randomized Trial Ming-Lung Yu, 1,3 Chia-Yen Dai, 1,3,4 Jee-Fu Huang, 4,5 Chang-Fu Chiu, 6 Yi-Hsin C. Yang,
More informationCorrelation between Apoptotic and Anti-apoptotic Proteins (caspase-3 and Bcl2) in Chronic Hepatitis C: An Immunohistochemical Study
KASR EL AINI MEDICAL JOURNAL VOL. 17, NO 3, October 2011 1 Correlation between Apoptotic and Anti-apoptotic Proteins (caspase-3 and Bcl2) in Chronic Hepatitis C: An Immunohistochemical Study Samia El-Naggar
More informationDifferential Diagnosis of NAFLD- A Short Summary:
Differential Diagnosis of NAFLD- A Short Summary: Almost a fifth of our general pediatric population is now classified as overweight in the United States. When such children present with elevated liver
More informationNON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) IN MEN WITH TYPE 2 DIABETES
NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) IN MEN WITH TYPE 2 DIABETES D. Bakalov 1, M. Boyanov 1, G. Sheinkova 1, L. Vezenkova 1, G. Prodanova 2, V. Christov 1 1 Endocrinology Clinic 2 Sonography unit
More informationTransmission of HCV in the United States (CDC estimate)
Transmission of HCV in the United States (CDC estimate) Past and Future US Incidence and Prevalence of HCV Infection Decline among IDUs Overall incidence Overall prevalence Infected 20+ years Armstrong
More informationAntiviral Therapy 14:187 193. Infectious Diseases Department, Centre d Investigation de la Fibrose Hépatique, Bourdeaux, France 5
Antiviral Therapy 14:187 193 Original article Overestimation of liver fibrosis staging using transient elastography in patients with chronic hepatitis C and significant liver inflammation Eugenia Vispo
More informationPatterns of abnormal LFTs and their differential diagnosis
Patterns of abnormal LFTs and their differential diagnosis Professor Matthew Cramp South West Liver Unit and Peninsula Schools of Medicine and Dentistry, Plymouth Summary liver function / liver function
More informationWhat to Do with the Patient With Abnormal Liver Enzymes? Nizar N. Zein, M.D. The Cleveland Clinic
What to Do with the Patient With Abnormal Liver Enzymes? Nizar N. Zein, M.D. The Cleveland Clinic Introduction Elevated liver enzymes is often not a clinical problem by itself. However it is a warning
More information1. PATHOPHYSIOLOGY OF METABOLIC SYNDROME
1. PATHOPHYSIOLOGY OF METABOLIC SYNDROME Izet Aganović, Tina Dušek Department of Internal Medicine, Division of Endocrinology, University Hospital Center Zagreb, Croatia 1 Introduction The metabolic syndrome
More informationBody Composition & Longevity. Ohan Karatoprak, MD, AAFP Clinical Assistant Professor, UMDNJ
Body Composition & Longevity Ohan Karatoprak, MD, AAFP Clinical Assistant Professor, UMDNJ LONGEVITY Genetic 25% Environmental Lifestyle Stress 75% BMI >30 OBESE 25-30 OVERWEIGHT 18-25 NORMAL WEIGHT 18
More informationIndian Journal of Medical Research and Pharmaceutical Sciences September 2015; 2(9) ISSN: ISSN: 2349-5340 Impact Factor (PIF): 2.
A STUDY OF LIPID PROFILE AND HEPATIC STEATOSIS IN CHRONIC HEPATITIS C VIRUS INFECTED EGYPTIAN PATIENTS. Afaf Masoud, Heba Abdella, Mostafa Hamed, Shereen A. Saleh, Amir Helmy MD, professor of Tropical
More informationHepatitis C. Laboratory Tests and Hepatitis C
Hepatitis C Laboratory Tests and Hepatitis C If you have hepatitis C, your doctor will use laboratory tests to check your health. This handout will help you understand what the major tests are and what
More informationKe-Qin Hu 1, *, Namgyal L. Kyulo 1, Eric Esrailian 2, Kevin Thompson 3, Resa Chase 4, Donald J. Hillebrand 5, Bruce A. Runyon 5
Journal of Hepatology 40 (2004) 147 154 www.elsevier.com/locate/jhep Overweight and obesity, hepatic steatosis, and progression of chronic hepatitis C: a retrospective study on a large cohort of patients
More informationEpidemiology of Hepatitis C Infection. Pablo Barreiro Service of Infectious Diseases Hospital Carlos III, Madrid
Epidemiology of Hepatitis C Infection Pablo Barreiro Service of Infectious Diseases Hospital Carlos III, Madrid Worldwide Prevalence of Hepatitis C 10% No data available WHO.
More informationHepatitis C. David Mutimer Queen Elizabeth Hospital Liver Unit Birmingham. Substance Misuse Treatment in the West Midlands. How can we reduce harm?
Hepatitis C David Mutimer Queen Elizabeth Hospital Liver Unit Birmingham Substance Misuse Treatment in the West Midlands. How can we reduce harm? Birmingham October 19 th 2007 infection HCV Natural History
More informationProtein Intake in Potentially Insulin Resistant Adults: Impact on Glycemic and Lipoprotein Profiles - NPB #01-075
Title: Protein Intake in Potentially Insulin Resistant Adults: Impact on Glycemic and Lipoprotein Profiles - NPB #01-075 Investigator: Institution: Gail Gates, PhD, RD/LD Oklahoma State University Date
More informationComparative Levels of ALT, AST, ALP and GGT in Liver associated Diseases
Available online at wwwpelagiaresearchlibrarycom European Journal of Experimental Biology, 2013, 3(2):280-284 ISSN: 2248 9215 CODEN (USA): EJEBAU Comparative Levels of ALT, AST, ALP and GGT in Liver associated
More informationKaohsiung Medical University; 5 Department of Occupational and Environmental Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
COMPARISON OF CLINICAL APPLICATION OF THE ABBOTT HBV PCR KIT AND THE VERSANT HBV DNA 3.0 TEST TO MEASURE SERUM HEPATITIS B VIRUS DNA IN TAIWANESE PATIENTS Jeng-Fu Yang, 1,2 Ya-Yun Lin, 1 Jee-Fu Huang,
More informationSteatosis Colorimetric Assay Kit
Steatosis Colorimetric Assay Kit Item No. 10012643 www.caymanchem.com Customer Service 800.364.9897 Technical Support 888.526.5351 1180 E. Ellsworth Rd Ann Arbor, MI USA TABLE OF CONTENTS GENERAL INFORMATION
More informationSHAHID AZIZ DO, FACOI.
SHAHID AZIZ DO, FACOI. ASSOCIATE CLINICAL PROFESSOR OF GI AND LIVER DISEASE. UT SOUTHWESTERN HEALTH SCIENCE CENTER, DALLAS ADJUNCT CLINICAL ASSISTANT PROFESSOR DEPT OF MEDICINE UNT HEALTH SCIENCE CENTER
More informationTreatment of Acute Hepatitis C
Management of Patients with Viral Hepatitis, Paris, 2004 Treatment of Acute Hepatitis C Michael P. Manns, Andrej Potthoff, Elmar Jaeckel, Heiner Wedemeyer Hepatitis C Virus (HCV) infection is a common
More informationLIVER. Update on Staging of Fibrosis and Cirrhosis. Staging and Liver Fibrosis. Stage is more than liver fibrosis
Linda Ferrell, MD Distinguished Professor Vice Chair Director of Surgical Pathology Dept of Pathology LIVER Update on Staging of Fibrosis and Cirrhosis Staging and Liver Fibrosis Two important concepts
More informationELEMENTS FOR A PUBLIC SUMMARY. Overview of disease epidemiology. Summary of treatment benefits
VI: 2 ELEMENTS FOR A PUBLIC SUMMARY Bicalutamide (CASODEX 1 ) is a hormonal therapy anticancer agent, used for the treatment of prostate cancer. Hormones are chemical messengers that help to control the
More informationThe Epidemiology of Hepatitis A, B, and C
The Epidemiology of Hepatitis A, B, and C Jamie Berkes M.D. University of Illinois at Chicago jberkes@uic.edu Epidemiology: Definitions The study of the incidence and prevalence of diseases in large populations
More informationPREVENTION OF HCC BY HEPATITIS C TREATMENT. Morris Sherman University of Toronto
PREVENTION OF HCC BY HEPATITIS C TREATMENT Morris Sherman University of Toronto Pathogenesis of HCC in chronic hepatitis C Injury cirrhosis HCC Injury cirrhosis HCC Time The Ideal Study Prospective randomized
More informationCommonly Asked Questions About Chronic Hepatitis C
Commonly Asked Questions About Chronic Hepatitis C From the American College of Gastroenterology 1. How common is the hepatitis C virus? The hepatitis C virus is the most common cause of chronic viral
More informationHepatic steatosis, the accumulation of lipids in. Long-Term Follow-up of Patients With NAFLD and Elevated Liver Enzymes
Long-Term Follow-up of Patients With NAFLD and Elevated Liver Enzymes Mattias Ekstedt, 1 Lennart E. Franzén, 2 Ulrik L. Mathiesen, 3 Lars Thorelius, 4 Marika Holmqvist, 5 Göran Bodemar, 1 and Stergios
More informationAlbumin. Prothrombin time. Total protein
Hepatitis C Fact Sheet February 2016 www.hepatitis.va.gov Laboratory Tests and Hepatitis If you have hepatitis C, your doctor will use laboratory tests to about learn more about your individual hepatitis
More informationHigh Blood Cholesterol
National Cholesterol Education Program ATP III Guidelines At-A-Glance Quick Desk Reference 1 Step 1 2 Step 2 3 Step 3 Determine lipoprotein levels obtain complete lipoprotein profile after 9- to 12-hour
More informationGT-020 Phase 1 Clinical Trial: Results of Second Cohort
GT-020 Phase 1 Clinical Trial: Results of Second Cohort July 29, 2014 NASDAQ: GALT www.galectintherapeutics.com 2014 Galectin Therapeutics inc. Forward-Looking Statement This presentation contains, in
More informationHepatitis C Treatment Expansion Initiative Multi-Site Conference Call. March 16, 2011
Hepatitis C Treatment Expansion Initiative Multi-Site Conference Call March 16, 2011 Case Presentations Kansas City Free Health Clinic Carilion Clinic Didactic Session Challenges in Determining HCV Treatment
More informationALPHA (TNFa) IN OBESITY
THE ROLE OF TUMOUR NECROSIS FACTOR ALPHA (TNFa) IN OBESITY Alison Mary Morris, B.Sc (Hons) A thesis submitted to Adelaide University for the degree of Doctor of Philosophy Department of Physiology Adelaide
More informationLIVER FUNCTION TESTS AND STATINS
LIVER FUNCTION TESTS AND STATINS Philippe J. Zamor and Mark W. Russo Current Opinion in Cardiology 2011,26:338 341 SUMMARY Purpose of review: To discuss recent data on statins in patients with elevated
More informationViral Hepatitis. 2009 APHL survey report
Issues in Brief: viral hepatitis testing Association of Public Health Laboratories May Viral Hepatitis Testing 9 APHL survey report In order to characterize the role that the nation s public health laboratories
More informationEpidemiology of HCV and HIV/HCV Infection in Guangzhou, China. Title. Charles Wang, M.D.
Epidemiology of HCV and HIV/HCV Infection in Guangzhou, China Title Charles Wang, M.D. Background Hepatitis C infects 170 million worldwide & 3 million Chinese HIV infects 33.3 million worldwide & 740,000
More informationMEDICAL POLICY STATEMENT
MEDICAL POLICY STATEMENT Original Effective Date Next Annual Review Date Last Review / Revision Date 5/21/2014 3/24/2016 3/24/2015 Policy Name Policy Number Hepatitis C Oral SRx-0003 Medical Policy Statements
More informationThe Prevalence and Determinants of Undiagnosed and Diagnosed Type 2 Diabetes in Middle-Aged Irish Adults
The Prevalence and Determinants of Undiagnosed and Diagnosed Type 2 Diabetes in Middle-Aged Irish Adults Seán R. Millar, Jennifer M. O Connor, Claire M. Buckley, Patricia M. Kearney, Ivan J. Perry Email:
More informationRecommendations for the Identification of Chronic Hepatitis C virus infection Among Persons Born During 1945-1965
Recommendations for the Identification of Chronic Hepatitis C virus infection Among Persons Born During 1945-1965 MMWR August 17, 2012 Prepared by : The National Viral Hepatitis Technical Assistance Center
More informationPreface. TTY: (888) 232-6348 or cdcinfo@cdc.gov. Hepatitis C Counseling and Testing, contact: 800-CDC-INFO (800-232-4636)
Preface The purpose of this CDC Hepatitis C Counseling and Testing manual is to provide guidance for hepatitis C counseling and testing of individuals born during 1945 1965. The guide was used in draft
More informationGlobal Under Diagnosis of Viral Hepatitis
Global Under Diagnosis of Viral Hepatitis Mel Krajden MD, FRCPC Medical Head, Hepatitis Clinical Prevention Services Associate Medical Director, Public Health Microbiology & Reference Laboratory BC Centre
More informationRenal cell carcinoma and body composition:
Renal cell carcinoma and body composition: Results from a case-control control study Ryan P. Theis, MPH Department of Epidemiology and Biostatistics College of Public Health and Health Professions University
More informationHepatitis B and C Co-infection. Mark Hull MHSc, FRCPC Clinical Assistant Professor Division of AIDS
Hepatitis B and C Co-infection Mark Hull MHSc, FRCPC Clinical Assistant Professor Division of AIDS Objectives Review natural history of hepatitis coinfection Brief overview of treatment indications for
More informationNUTRITION IN LIVER DISEASES
NUTRITION IN LIVER DISEASES 1. HEPATITIS: Definition: - Viral inflammation of liver cells. Types: a. HAV& HEV, transmitted by fecal-oral route. b. HBV & HCV, transmitted by blood and body fluids. c. HDV
More informationHCV and Diabetes. Francesco Negro. University Hospital of Geneva, Switzerland HepDART, Tuesday, December 10 th, 2013, Big Island, HI
HCV and Diabetes Francesco Negro University Hospital of Geneva, Switzerland HepDART, Tuesday, December 10 th, 2013, Big Island, HI Host genes Sedentary lifestyle HCV Drugs Environmental toxins (bisphenol
More informationLiver Transplantation for Hepatocellular Carcinoma. John P. Roberts, MD Chief, Division of Transplant Service University of California, San Francisco
Liver Transplantation for Hepatocellular Carcinoma John P. Roberts, MD Chief, Division of Transplant Service University of California, San Francisco Hepatocellular Carcinoma HCC is the 5th most common
More informationThe Progression of Liver Damage in Chronic Hepatosis
Steatosis Accelerates the Progression of Liver Damage of Chronic Hepatitis C Patients and Correlates With Specific HCV Genotype and Visceral Obesity LUIGI E. ADINOLFI, MICHELE GAMBARDELLA, AUGUSTO ANDREANA,
More informationUpdate on Hepatitis C. Sally Williams MD
Update on Hepatitis C Sally Williams MD Hep C is Everywhere! Hepatitis C Magnitude of the Infection Probably 8 to 10 million people in the U.S. are infected with Hep C 30,000 new cases are diagnosed annually;
More informationReview: How to work up your patient with Hepatitis C
Review: How to work up your patient with Hepatitis C You screened your patient, and now the HCV antibody test is positive. What do you do next? The antibody test only means they have been exposed to HCV.
More informationHIGHLIGHTS FROM THE AASLD MEETING. Rob Goldin. Imperial College Faculty of Medicine at St Mary s r.goldin@imperial.ac.uk
HIGHLIGHTS FROM THE AASLD MEETING Rob Goldin Imperial College Faculty of Medicine at St Mary s r.goldin@imperial.ac.uk What was on at the meeting? 1. Postgraduate Course 2. Oral Presentations 3. Poster
More informationThe State of the Liver in the Adult Patient after Fontan Palliation
The State of the Liver in the Adult Patient after Fontan Palliation Fred Wu, M.D. Boston Adult Congenital Heart Service Boston Children s Hospital/Brigham & Women s Hospital 7 th National Adult Congenital
More informationAfter the Cure: Long-Term Management of HCV Liver Disease Norah A. Terrault, MD, MPH
After the Cure: Long-Term Management of HCV Liver Disease Norah A. Terrault, MD, MPH Professor of Medicine Department of Gastroenterology Director, Viral Hepatitis Center University of California San Francisco
More informationHepatitis C Treatment Criteria Commercial & Minnesota Health Care Programs
Last update: February 23, 2015 Hepatitis C Treatment Criteria Commercial & Minnesota Health Care Programs Please see healthpartners.com for Medicare coverage criteria. Table of Contents 1. Harvoni 2. Sovaldi
More informationHCV: Diagnostic Testing and Staging. HCV: Diagnostic Tests
HCV: Diagnostic Testing and Staging HCV: Diagnostic Tests Necessary HCV Antibody HCV-RNA Genotype Not Necessary ALT IL28 B 1 ALT as a Sole Trigger for Screening Misses Some Infected Patients Patients*
More information1333 Plaza Blvd, Suite E, Central Point, OR 97502 * www.mountainviewvet.net
1333 Plaza Blvd, Suite E, Central Point, OR 97502 * www.mountainviewvet.net Diabetes Mellitus (in cats) Diabetes, sugar Affected Animals: Most diabetic cats are older than 10 years of age when they are
More informationAntioxidant response in patients with chronic hepatitis B or C.
Antioxidant response in patients with chronic hepatitis B or C. Kamila Wójcik, Anna Piekarska, Elżbieta Jabłonowska Department of Infectious Diseases and Hepatology, Medical University of Lodz, Poland
More informationStudy of Thrombocytopenia in Chronic Hepatitis C
Thrombocytopenia in Chronic Hepatitis C Mihai Olariu 1, Cristina Olariu 2, Dan Olteanu 2 1) National Institute of Infectious Diseases Prof. Dr. Matei Balş ; 2) University of Medicine and Pharmacy Carol
More informationLiver Biopsy in Patients Infected with Chronic Hepatitis C and Persistently Normal Serum ALT Levels
Original Article Liver Biopsy in Patients Infected with Chronic Hepatitis C and Persistently Normal Serum ALT Levels M. Sadik Memon, Akber Memon, M. Hanif Ghani, Noman Khan, Naresh K Khatri, Siraj Memon,
More informationApproach to Abnormal Liver Tests
Approach to Abnormal Liver Tests Naga P. Chalasani, MD, FACG Professor of Medicine and Cellular & Integrative Physiology Director, Division of Gastroenterology and Hepatology Indiana University School
More informationHCV in 2020: Any cases left? Rafael Esteban Hospital General Universitario Valle Hebron Barcelona. Spain
HCV in 2020: Any cases left? Rafael Esteban Hospital General Universitario Valle Hebron Barcelona. Spain Yes, still too many Measures to eradicate an Infectious Disease Prevention: Vaccination Screening
More informationLedipasvir/Sofosbuvir (Harvoni) for Treatment of Hepatitis C
Ledipasvir/Sofosbuvir (Harvoni) for Treatment of Hepatitis C Policy Number: Original Effective Date: MM.04.034 12/1/2014 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 12/1/2014
More informationDiabetes Brief. Pre diabetes occurs when glucose levels are elevated in the blood, but are not as high as someone who has diabetes.
Diabetes Brief What is Diabetes? Diabetes mellitus is a disease of abnormal carbohydrate metabolism in which the level of blood glucose, or blood sugar, is above normal. The disease occurs when the body
More informationHepatitis C Class Review
Hepatitis C Class Review Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-945-5220 Fax 503-947-1119 Month/Year of Review: January
More informationSovaldi (sofosbuvir) Prior Authorization Criteria
INITIAL REVIEW CRITERIA Sovaldi (sofosbuvir) Prior Authorization Criteria 1. Adult patient age 18 years old; AND 2. Prescribed by a hepatologist, gastroenterologist, infectious disease specialist, transplant
More informationNew treatment options for HCV: implications for the Optimal Use of HCV Assays
New treatment options for HCV: implications for the Optimal Use of HCV Assays Hans Orlent Dept. of Gastroenterology & Hepatology AZ Sint Jan Brugge-Oostende, Brugge This program is supported by educational
More informationCHAPTER V DISCUSSION. normal life provided they keep their diabetes under control. Life style modifications
CHAPTER V DISCUSSION Background Diabetes mellitus is a chronic condition but people with diabetes can lead a normal life provided they keep their diabetes under control. Life style modifications (LSM)
More information2.5 Cancer of the liver
ALCOHOL CONSUMPTION 399 2.4.7 Effect modification The combined effects of smoking and alcoholic beverage consumption on the development of cancer of the oesophagus have been examined in several studies
More information